FIGURE 2.

In vitro effect of montelukast on platelet–leukocyte aggregate formation induced by COVID-19 plasma. Whole blood (WB) from healthy subjects (HS; n = 6), pre-incubated with montelukast (1 µM) as indicated, was plasma-depleted and reconstituted with COVID-19 plasma pools (dark gray bars) or autologous plasma (light gray bars). Total (A,B) and TF^pos (C,D)-platelet–leukocyte aggregates was  measured by flow cytometry. Data are reported as mean ± SD. ***p < 0.001 (TF, tissue factor; plt, platelets; mono, monocytes; gran, granulocytes).